In view of the observed SHBsAg/MOG cross-reactivity, the vaccine's possible role as an immunomodulator of viral/self cross-reactivity must be further investigated. Cross reacting antigens are identified by immunoblotting using anti-Candida antisera. Tissue antigen preparations or food extracts are analyzed by electrophoresis. None of the vaccinees reported symptoms of demyelinating disorders. A method of determining immunological cross reactivity between Candida and human tissue or food antigens. There was no reactivity to the SHBsAg/MBP mimics. At 6 months post-vaccination, 3 of the 4 anti-MOG reactive cases before vaccination and 7 of the 24 (29%) of the anti-MOG reactive cases at 3 months post-vaccination had lost their reactivity to MOG5-24. SHBsAg/MOG double reactivity was cross-reactive as confirmed by inhibition studies. Such reactions may be to different foods containing. Overall 30/50 (60%) vaccinees had SHBsAg/MOG double reactivity on at least one occasion compared to none before-vaccination and in 2 (2%) of the pathological controls (p < 0.001 for both). Individuals who react to specific food allergens, inhalants or substances can develop an allergy to others. Jpn J Exp Med 46 ( 2 ) : 123-33, Apr 76 Immunologic cross - reactivity. Reactivity to at least one of the MOG mimics was present in 4 (8%) pre-HBvacc and in 30 (60%) post-HBvacc (p < 0.001). J Clin Microbiol 2 ( 6 ) : 528-30, Dec 75 Antibody response to group A. Reactivity to at least one of the SHBsAg peptides was found in 8 (14%) pre-HBvacc subjects amongst the remaining 50, reactivity to at least one of the SHBsAg peptides appeared in 47 (94%) post-HBvacc. Eighty-seven sera from anti-SHBsAg antibody negative patients with various diseases were tested as pathological controls. A total of 147 samples from 58 adults were collected before HBvacc (58/58), and post-HBvacc (48/58 before the second and 41/58 before the third boost). Twenty-mer peptides spanning 4 SHBsAg/MOG and 1 SHBsAg/MBP mimicking pairs, were constructed and tested by ELISA as targets of cross-reactive responses. Abdominal pain, diarrhea, nausea or vomiting. Immune responses to therapeutic protein products may pose problems for both patient safety and product efficacy. Wheezing, nasal congestion or trouble breathing. Swelling of the lips, face, tongue and throat or other parts of the body. The most common food allergy signs and symptoms include: Tingling or itching in the mouth. On the basis of the reported association between hepatitis B vaccination (HBvacc) and autoimmune demyelinating complications such as multiple sclerosis (MS), we have looked for aminoacid similarities between the small hepatitis B virus surface antigen (SHBsAg), and the MS-autoantigens myelin basic protein (MBP) and myelin oligodendrocyte glycoprotein (MOG) that could serve as targets of immunological cross-reactivity. Rarely, symptoms may be delayed for several hours.
0 Comments
Leave a Reply. |